Medicine

ProtoKinetix AAGP® Dry Eye Program Advancing

Tuesday, July 7, 2020 - 1:30pm

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye Disease Program.

Key Points: 
  • ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye Disease Program.
  • Dry Eye Disease (DED) ProtoKinetix is expecting closure of agreements for the first steps in a roll-out of a new product line development that will test AAGP for treatments related to Dry Eye Disease.
  • We are pleased with the progress made with respect to the expansion of ProtoKinetixs Dry Eye Disease program.
  • It is important that each person reviewing this release understand the significant risks attendant to the operations of ProtoKinetix.

Humanigen Appoints Senior Executives to Management Team

Tuesday, July 7, 2020 - 12:00pm

Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that several executives have been appointed to key positions at Humanigen.

Key Points: 
  • Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced that several executives have been appointed to key positions at Humanigen.
  • All three positions report to Cameron Durrant, MD, MBA, Chief Executive Officer, Humanigen.
  • He is also the founder of Black Horse Capital with decades of biotechnology investment experience.
  • We are pleased that both Dr. Chappell and Mr. Tousley, who have previously operated in interim capacities with the Company, have joined us as full-time members of the Humanigen team, stated Dr. Cameron Durrant.

MAIA Biotechnology, Inc. Announces Publication in Cancer Cell of Encouraging Data on the Immunogenic Effects of Its Flagship Product Candidate THIO

Tuesday, July 7, 2020 - 1:00pm

Preclinical data have demonstrated that THIO kills cancer cells by targeting and uncapping telomeres thereby inducing DNA damage.

Key Points: 
  • Preclinical data have demonstrated that THIO kills cancer cells by targeting and uncapping telomeres thereby inducing DNA damage.
  • The latest preclinical data showed this is complemented by an immunogenic effect, which may allow for more durable outcomes when used sequentially with immunotherapy.
  • In these preclinical studies published in Cancer Cell, investigators demonstrated that THIO leads to tumor regression through induction of innate and adaptive host immune system responses.
  • We believe the publication of these unprecedented immunogenic effects of THIO in Cancer Cell provides additional validation for this innovative program.

Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease

Tuesday, July 7, 2020 - 1:00pm

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced development plans to support a New Drug Application (NDA) for the novel investigational reactive aldehyde species (RASP) inhibitor reproxalap in dry eye disease.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced development plans to support a New Drug Application (NDA) for the novel investigational reactive aldehyde species (RASP) inhibitor reproxalap in dry eye disease.
  • In addition, a safety trial in dry eye disease patients is expected to be initiated in the fourth quarter of 2020.
  • Reproxalap is a novel investigational small-molecule immune-modulating covalent inhibitor of RASP in development as a topically administered ophthalmic solution for dry eye disease and allergic conjunctivitis.
  • 2016, 41(9):1143-9; Reproxalap preclinical and Phase 2a in dry eye disease clinical trial results on file.

Reven Publishes New COVID-19 Related Articles Outlining Clinical Impact Potential of Its RJX Platform

Tuesday, July 7, 2020 - 1:09pm

Ph.D., and other members of the Reven team and their academic collaborators in the medical journal, Clinical Investigation (London).

Key Points: 
  • Ph.D., and other members of the Reven team and their academic collaborators in the medical journal, Clinical Investigation (London).
  • The article also discusses the potential for the prevention of life-threatening complications from COVID-19 with RJX based on data obtained from clinical and non-clinical studies.
  • She provides the critical design elements for a two-cohort, two-part placebo-controlled, double-blind Phase 2 study of RJX in COVID-19 patients.
  • Clinical Impact Potential Of Rejuveinix (RJX) For Prevention Of Fatal Acute Respiratory Distress Syndrome (ARDS) And Multi-Organ Failure In Covid-19 Patients.

Turner Imaging Systems and Siemens Healthineers Announce New Business Relationship Agreement

Tuesday, July 7, 2020 - 1:02pm

Turner Imaging Systems has entered into a Master Resellers agreement which will add the Smart-C Mini C-Arm to the Siemens Healthineers portfolio of radiology and imaging products.

Key Points: 
  • Turner Imaging Systems has entered into a Master Resellers agreement which will add the Smart-C Mini C-Arm to the Siemens Healthineers portfolio of radiology and imaging products.
  • The Smart-C Mini C-Arm, developed by Turner Imaging Systems, is a fully functional mini-C-arm system that is battery operated and hand-transportable, improving the way fluoroscopy is performed.
  • Turner Imaging Systems, based in Orem, Utah, recently received FDA 510(k) clearance of the Smart-C Mini C-Arm portable fluoroscopy X-ray imaging device.
  • As a developer of advanced X-ray imaging systems, the inclusion of the Smart-C Mini C-Arm in the Siemens portfolio represents a significant milestone, not only for Turner Imaging Systems but also for the imaging communitypatients and clinicians.

Novocure Enrolls Last Patient in HEPANOVA Trial Testing Tumor Treating Fields in Combination with Sorafenib in Advanced Liver Cancer

Tuesday, July 7, 2020 - 12:30pm

Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced that the last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer.
  • We look forward to seeing results from the HEPANOVA trial and further exploring the potential of Tumor Treating Fields as a treatment for advanced liver cancer.
  • The safety and effectiveness of treatment with Tumor Treating Fields for liver cancer has not been established.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer.

LivaNova Announces Publication Detailing the Design of the RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression

Tuesday, July 7, 2020 - 2:00pm

Working with CMS, we designed RECOVER the largest clinical study of its kind to further evaluate and confirm the efficacy of VNS Therapy for TRD, said Bryan Olin, LivaNova Senior Vice President for Clinical, Quality and Regulatory Affairs.

Key Points: 
  • Working with CMS, we designed RECOVER the largest clinical study of its kind to further evaluate and confirm the efficacy of VNS Therapy for TRD, said Bryan Olin, LivaNova Senior Vice President for Clinical, Quality and Regulatory Affairs.
  • More information about the RECOVER study is available at ClinicalTrials.gov and at recovervns .com.
  • LivaNova operates as two businesses: Cardiovascular and Neuromodulation, with operating headquarters in Mirandola (Italy) and Houston (U.S.), respectively.
  • These statements include, but are not limited to, statements regarding VNS Therapy and our approach to treatment-resistant depression using VNS Therapy.

Ardent Health Services Selects American Red Cross Resuscitation Suite™ Program in Enterprise-wide Agreement with HealthStream

Tuesday, July 7, 2020 - 2:25pm

HealthStream (Nasdaq: HSTM) announced today that Ardent Health Services has entered into an agreement with HealthStream to utilize the American Red Cross Resuscitation Suite program, enterprise-wide, for resuscitation skills training and certification, which will be provided through HealthStreams workforce platform.

Key Points: 
  • HealthStream (Nasdaq: HSTM) announced today that Ardent Health Services has entered into an agreement with HealthStream to utilize the American Red Cross Resuscitation Suite program, enterprise-wide, for resuscitation skills training and certification, which will be provided through HealthStreams workforce platform.
  • The Red Cross Resuscitation Suite program chosen by Ardent brings an updated, highly adaptive, competency-based solution to their healthcare teams, offering a new standard of resuscitation competency.
  • Ensuring competency of resuscitation knowledge and skills becomes more efficient, is achieved with higher quality learning effectiveness, and can be economically advantageous for health systems like Ardent with the adoption of the Red Cross Suite.
  • To learn more about the Red Cross Resuscitation Suite program and the quality improvements that hospitals and healthcare organizations are realizing from it, go to https://www.healthstream.com/solution/resuscitation/bls-als-pals .

Glytec and ThunderCat Technology Partner to Improve Glycemic Management at VA Hospitals

Tuesday, July 7, 2020 - 1:30pm

Glytec , the only provider of insulin management software across the continuum of care, and ThunderCat Technology , a Service-Disabled Veteran-Owned Small Business (SDVOSB) that delivers technology products and services to government organizations, today announced a partnership to help improve glycemic management within hospitals operated by the United States Department of Veterans Affairs (VA).

Key Points: 
  • Glytec , the only provider of insulin management software across the continuum of care, and ThunderCat Technology , a Service-Disabled Veteran-Owned Small Business (SDVOSB) that delivers technology products and services to government organizations, today announced a partnership to help improve glycemic management within hospitals operated by the United States Department of Veterans Affairs (VA).
  • Together, Glytec and ThunderCat will extend Glytecs reach into the VA health system by making Glytecs Glucommander software widely available to improve patient outcomes and reduce cost of care for the large population of veterans with diabetes.
  • However, that need is higher in VA hospitals because 25% of veteran patients are living with diabetes , compared to about 10% of the general public.
  • While inpatient glycemic management remains a broader issue across the U.S. health system, helping to improve care and outcomes at the VA is especially important and can have a very dramatic impact.